Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (71)	11/4/1998 8:58:00 AM
From: Tony van Werkhooven	Respond to of 1386

Gabe, I would like to second your post. I am a recent Pars investor and I am most enthused about the future prospects for the company. I am using current weakness to buy additional shares. I can understand the frustration on the part of longtime shareholders. Given the limited resources of the company (financial and human) it is necessary to prioritize- and I believe that the priorities are in the right place. On the other hand, it is quite clear in its approach that the leadership of this company has a research/ academic background, rather than marketing. Maybe, in ideal circumstance, we would like to have a little more in the marketing direction. However, from the perspective of a three year time horizon, this should make little difference, given the product pipeline that has been so ably discussed on this thread. The only risk to this scenario is if the need for additional outside financing arises. Ariella has made a strong case that this will probably not be required. Looking forward to reading your posts as a log term PARS shareholder. Tony

To: Gabe Fernandez who wrote (71)	11/4/1998 9:14:00 AM
From: Ron	Respond to of 1386

Greetings teammates....IMOH, I feel that what has been debated on this thread about the Pr firm doing good or bad is not exactly-(although close)- the point some, or I should say I, are trying to make. I do not want a quick temporary jump in the stock price and then let the shorties have their day again. I want us to be consevative and steady. We have great days ahead and a great company. However, I strongly feel that if we issued press releases that were aimed at the positives in the opening paragraph then what we would be doing is leaving people with a positive impression of our company rather than an initial feeling of "oh, another biotech losing money". We know that is untrue but do the potential investors who know little of our company get a positve impression from such a release as yesterdays? Yes, I believe the release was good for us, but FIRST impression sticks with people. And how do we know if potential investors even finished reading the release. I think that a consevative approach is the best way for our company, and I commend them for that, but a subtle change in press release would put a positive thought in one's head and when more good news comes forward these potential investors would get an immediate postive thought of our company in their mind, rather than the thought that "I must stay weary of this biotech." Well, I have gone on long enough. I probably make no sense to anyone other than myself, but these are my thoughts. I have been with this company for 2 1/2 years and will stay for many more years. I am not asking MGT. to go headhunting, but a more positive approach concerning press releases could not hurt. All opinions are welcomed and if I upset anyone, it was not intentional and I apologize. Best Regards, RON

To: Gabe Fernandez who wrote (71)	11/4/1998 9:36:00 AM
From: wolfdog2	Read Replies (3) \| Respond to of 1386

Gabe, I doubt very much that PARS's stock price is very much, if at all, influenced by what is posted here. The story is what it is and for better or worse, it is out. I think that people here are, for the most part--Ariella and Omer specifically excepted--in too much of a hurry. I'm frankly surprised at some of the posts by people whom I thought should know better. Investing in biotechs is a bit like making goulash. You put the ingredients in the pot and then sit back and let it simmer. In this case, of course, it is the company that puts the ingredients together and we as shareholders just sit back and watch them go about their business. And we have very capable management, both scientifically and financially, watching our pot. But the stock needs to simmer for a while. And while it does, the price may move lower. Especially if people perceive, as Richard trumpets, that PARS is about to run out of money. So the shorts may keep banging away at the stock while management goes about its business of finding a partner for HU 211 and moving other products through clinical trials and regulatory approvals. However, the company, as Ariella ably pointed out, is not running out of cash. Long before ten months are up, I expect PARS to have found a partner for HU 211 and received up front payments. Not only that, sales from current products are ramping up and should provide an additional cushion. So why isn't the stock doing better? Well, the most important factor is that we have no Wall St. analyst coverage. Absent some significant event, analyst coverage is the sine qua non of getting the share price moving. We do, of course, have two advisory letters (Neuroinvestor and Sturza) recommending the stock. But given the huge number of shares outstanding, these two advisory services alone aren't enough to lift the shares. When we get Wall St. coverage (and a positive recommendation) the stock will begin to perform. Unfortunately, there were by my count only two Wall St. firms on the conference call yesterday. At least only two asked questions. So absent Wall St. coverage, the next significant event which could give a dramatic boost to the stock will be the signing of a partner for HU 211. After the signing of a partner, I would also hope that we might get some Wall St. coverage. Until then, I doubt that much of anything is going to happen with the stock. So we all might just as well sit back and relax and, to return to my goulash example, wait while the pot simmers.